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Objectives This study sought to test the hypothesis that hyperpolarization-activated cyclic nucleotide–gated (HCN)–based
biological pacing might be improved significantly by hyperpolarizing the action potential (AP) threshold via coex-
pression of the skeletal muscle sodium channel 1 (SkM1).
Background Gene-based biological pacemakers display effective in vivo pacemaker function. However, approaches used to date
have failed to manifest optimal pacemaker properties, defined as basal beating rates of 60 to 90 beats/min, a brisk
autonomic response achieving maximal rates of 130 to 160 beats/min, and low to absent electronic backup pacing.
Methods We implanted adenoviral SkM1, HCN2, or HCN2/SkM1 constructs into left bundle branches (LBB) or left ventric-
ular (LV) epicardium of atrioventricular-blocked dogs.
Results During stable peak gene expression on days 5 to 7, HCN2/SkM1 LBB-injected dogs showed highly stable in vivo
pacemaker activity superior to SkM1 or HCN2 alone and superior to LV-implanted dogs with regard to beating
rates (resting approximately 80 beats/min; maximum approximately 130 beats/min), no dependence on electronic
backup pacing, and enhanced modulation of pacemaker function during circadian rhythm or epinephrine infusion. In
vitro isolated LV of dogs overexpressing SkM1manifested a significantly more negative AP threshold.
Conclusions LBB-injected HCN2/SkM1 potentially provides a more clinically suitable biological pacemaker strategy than
other reported constructs. This superiority is attributable to the more negative AP threshold and injection into
the LBB. (J Am Coll Cardiol 2013;61:1192–201) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.031Electronic cardiac pacing provides effective treatment for
heart block and/or sinus node dysfunction but has short-
comings, including inadequate autonomic modulation, lim-
ited battery life, lead fracture, and an association with
potentially deleterious cardiac remodeling (1). In seeking
better alternatives, we and others have explored diverse
strategies to create biological pacemakers (1). These strate-
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March 19, 2013:1192–201 Biological Pacing by HCN2/SkM1 Gene TransferRecent efforts have focused on improving gene-based bio-
logical pacemakers. However, engineered hyperpolarization-
activated cyclic nucleotide–gated (HCN) variants have provided
improvements that are subtle (e.g., HCN2 E324A) (2) or exces-
ive (e.g., HCN212) (3). Alternative strategies have included
verexpressing calcium-stimulated adenylyl cyclase (AC1) (4) or
he dominant negative inward rectifier channel Kir2.1AAA (5),
nd the combination strategies of HCN2/AC1 (4) or HCN2/
ir2.1AAA (5). Although these strategies represent substan-
ial improvements, no strategy has achieved the pre-defined
ptimal outcomes of: 1) basal beating rates of 60 to 90
eats/min; 2) autonomic responsiveness resulting in rate
ncreases to 130 to 160 beats/min; and 3) low to absent
ependence on electronic backup pacing (4,5).
To achieve these optimal parameters, we coexpressed
keletal muscle sodium channel 1 (SkM1) with HCN
hannel 2 (HCN2). Our rationale was as follows: HCN
hannels generate inward current that drives the membrane
oward threshold for the rapid inward sodium current (INa).
To reach the threshold for INa, channel opening must be
maximized. We have shown that the SkM1 sodium channel
has a more depolarized inactivation versus voltage curve and
more rapid recovery kinetics from inactivation than the cardiac
sodium channel SCN5A (6,7). Thus, SkM1 is expected to
provide greater availability of sodium channels during diastole,
leading to a more negative threshold potential, improved
pacemaker stability, and increased beating rates.
Methods
Experiments conformed to the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health publica-
tion 85-23, revised 1996) and were performed using proto-
cols approved by the Columbia University Institutional
Animal Care and Use Committee.
Intact canine studies. Adult mongrel dogs were prepared,
anesthetized, and fitted with electronic pacemakers (VVI 35
beats/min) and underwent radiofrequency ablation of the
atrioventricular node as described previously (2). One series
of animals was injected in the left bundle branch (LBB)
with the appropriate adenovirus construct to obtain the
following groups: HCN2 (n  12), including 7 previously
reported HCN2/green fluorescent protein (GFP)-treated
animals (8), 3 current HCN2/GFP-treated animals, and 2
animals injected with HCN2 plus empty vector; SkM1/GFP
(designated SkM1; n  6); and HCN2/SkM1 (n  6).
Outcomes in the HCN2/empty group were comparable to
those with HCN2/GFP and were therefore combined into
one group designated HCN2.
Left thoracotomies were performed on a second series
of animals using previously described methods (6), and
adenovirus constructs were injected into 3 left ventricular
(LV) anterobasal epicardial sites to obtain the following
groups: HCN2/GFP (n  10; designated HCN2), SkM1/
GFP (n  7; designated SkM1), and HCN2/SkM1 (n  6).
Injections were in close proximity (approximately 4 mm) aof one another. The injection
site was marked with 2 sutures.
Further experimental details
and statistical analysis details are
in the Online Appendix.
Results
Intact animal studies. BASELINE
UNCTION. Biological pacing ef-
ectiveness was evaluated in light
f baseline heart rates, escape
imes after overdrive pacing, and
ercentage time during which the
ackup electronic pacemaker drove
he heart (Fig. 1). These parame-
ers were compared in animals in-
ected with biological pacemakers
nto the LBB or LV subepicardium.
lectrocardiograms (ECGs) were
ecorded while animals rested quietly on a table (baseline
eating rates). Over 7 days, biological pacemaker function in
CN2/SkM1 LBB-injected animals was superior (i.e., faster
asal rates, shorter escape times, and lower percentage of
lectronically stimulated beats) to that of animals with HCN2
r SkM1 alone and was superior to that of animals with
V subepicardial injection of HCN2/SkM1. Typical
aseline ECGs and escape times of LBB-injected animals
re shown in Online Figure 1 and immunochemical
taining of LBB revealing presence of HCN2 and SkM1
s shown in Online Figure 2.
AUTONOMIC MODULATION. Sensitivity to autonomic mod-
ulation of pace-mapped rhythms was studied via 24-h ECG
recordings. Faster beating rates were reached in HCN2/
SkM1 LBB-injected animals than those injected with
HCN2 or SkM1 (Fig. 2A). At 5 to 7 days, beating rates were
ignificantly faster in animals that received HCN2/SkM1
nto the LBB as compared with subepicardial injection
Fig. 2B). Typical recordings of maximal beating rates in
BB-injected animals are in Figures 2C, 2D, and 2E.
A detailed analysis of percentage pace-mapped rhythms
nd their autonomic modulation was performed on the
CG Holter recordings at 5 to 7 days. The percentage of
atching pace-mapped beats was significantly higher in
CN2/SkM1 LBB-injected animals (95% of all beats),
equiring less pacemaker backup than the respective HCN2-
nd SkM1-injected groups (p  0.05) (Fig. 3A). The
ercentage of matching beats in animals that received
CN2/SkM1 into subepicardium was lower (approximately
0%) and did not differ from that of HCN2 and SkM1
ontrol groups. Animals injected with SkM1 alone either
nto the subepicardium or LBB showed persistent bigeminy
r trigeminy in more than 10% of beats, whereas no such
Abbreviations
and Acronyms
AC1  adenylyl cyclase 1
AP  action potential
HCN2  hyperpolarization-
activated cyclic nucleotide–
gated channel 2
hMSC  human
mesenchymal stem cell
HRV  heart rate variability
Kir2.1AAA  dominant
negative inward rectifier
channel
LBB  left bundle branch
LV  left
ventricle/ventricular
SkM1  skeletal muscle
sodium channel 1rrhythmias were detected in animals injected with HCN2
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Biological Pacing by HCN2/SkM1 Gene Transfer March 19, 2013:1192–201or HCN2/SkM1 (p  0.05) (Fig. 3A). The percentage of
lectronically paced beats was reduced in the HCN2/SkM1-
BB group to 0% of all beats (p  0.05 vs. respective
CN2 and SkM1 groups) (Fig. 3A). The 24-h average rate
f pace-mapped rhythms is summarized in Figure 3B,
howing a faster rate in HCN2/SkM1-LBB versus the
CN2-LBB and SkM1-LBB groups (p  0.05). These
esults are consistent with the 5- to 7-day averages of
aseline and maximal beating rates reported in Figure 2.
inally, animals that received HCN2 into the LBB exhibited
aster 24-h average beating rates than animals that received
Figure 1 HCN2/SkM1-Based Biological Pacemakers Exhibit Im
SkM1, With LBB Injection Providing Superior Outcom
(A to C) Summary data for left bundle block (LBB)–injected animals receiving hype
muscle sodium channel 1 (SkM1; n  5 in A and B, n  6 in C), or HCN2/SkM1
animals than in animals injected with only HCN2 or SkM1 (*). (B) Mean escape t
animals (*). (C) Median percentage of electronically stimulated beats calculated o
injected animals. On days 4 to 7, electronic backup pacing was eliminated in HCN
receiving HCN2 (n  10), SkM1 (n  7), or HCN2/SkM1 (n  6). (D) Mean basel
stimulated beats. (G to I) Summary data pooled for days 5 to 7. (G) Baseline bea
jected animals receiving either HCN2 or SkM1 (†). (H) Escape times in LBB-injecte
the respective subepicardial injections (‡). Escape times of HCN2/SkM1-injected animal
centage of electronically stimulated beats was reduced to 0% in LBB-injected animals re
HCN2 (*) or in subepicardially injected animals receiving HCN2/SkM1 (‡). Note that inCN2 into the subepicardium (p  0.05) (Fig. 3B).To test whether the changes in beating rate and depen-
ence on backup electronic pacing were consistent with
hat would be expected based on a normal circadian
hythm, we compared these parameters during 2 h of sleep
2:00 to 4:00 AM) with 2 h of feeding and activity (8:00 to
0:00 AM). Regardless of injection site, HCN2 and HCN2/
SkM1 groups exhibited a significant rate acceleration of
pace-mapped rhythms from morning to night (p  0.05)
(Fig. 3C). During sleep as well as during feeding and
activity, pace-mapped rhythms were significantly faster in
HCN2/SkM1 LBB-injected animals as compared with those
d Function Over HCN2 and
Left Ventricular Myocardial Injection
ization-activated cyclic nucleotide–gated channel 2 (HCN2; n  12), skeletal
). (A) Baseline beating rates on days 3 to 7 were faster in HCN2/SkM1-injected
n days 4 to 7 were shorter in HCN2/SkM1-injected animals than HCN2-injected
-h periods were significantly lower in HCN2/SkM1-injected animals than HCN2-
1-injected animals. (D to F) Summary data for subepicardially injected animals
ating rates. (E) Mean escape times. (F) Median percentage of electronically
tes in LBB-injected animals receiving HCN2/SkM1 were faster than in LBB-in-
als receiving SkM1 or HCN2/SkM1 were significantly shorter compared with those of
significantly shorter than those of the respective HCN2 injections (*). (I) Median per-
HCN2/SkM1 and was significantly lower than in LBB-injected animals receiving
s C, F and I, error bars are presented as interquartile range. *†‡p  0.05.prove
es to
rpolar
(n  6
imes o
ver 24
2/SkM
ine be
ting ra
d anim
s were
ceiving
panelin HCN2-LBB and SkM1-LBB groups (p  0.05) (Fig. 3C).
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March 19, 2013:1192–201 Biological Pacing by HCN2/SkM1 Gene TransferFurthermore, both HCN2-LBB and HCN2/SkM1-LBB
groups exhibited faster beating rates in the morning than
the respective subepicardially injected groups (p  0.05)
(Fig. 3C). The percentage of electronically paced beats
during night and morning is summarized in Figure 3D.
Subepicardially or LBB-injected animals that received
HCN2 exhibited a lower percentage of electronic pacing in
the morning than at night (p  0.05) (Fig. 3D).
Poincaré plots of pace-mapped rhythms also demon-
strated differences in autonomic modulation as analyzed by
heart rate variability (HRV) among animals with the 3 gene
constructs injected into the LBB (Fig. 4A). Quantitative
analysis of SD parameters revealed that the level of para-
sympathetic modulation expressed by short-term variation
of heart rates (SD1) was comparable among the 3 groups
tested (Fig. 5B, left panel). Sympathetic modulation, ex-
pressed as long-term variation of heart rates (SD2), was
significantly reduced (i.e., normalized) in the HCN2/SkM1-
LBB group as compared with that of animals LBB-injected
with HCN2 (p  0.05) (Fig. 4B, middle panel). The
Figure 2 HCN2/SkM1-Based Biological Pacemakers Injected I
Have Faster Maximal Beating Rates Than Those Base
(A) Maximal pace-mapped beating rates in LBB-injected animals. Maximal beating
data pooled for days 5 to 7. Maximal pace-mapped beating rates in LBB-injected a
SkM1. LBB-injected animals also had significantly faster maximal beating rates th
HCN2 n  10, SkM1 n  7, HCN2/SkM1 n  6; LBB-injected animals: HCN2 n
every beat during 8 min surrounding an episode of maximal pace-mapped beating
maximal beating rates of the recordings shown on the left. (C) Gradual warm up an
beating rate in an SkM1-injected animal. (E) Stable baseline beating and robust ra
viations as in Figure 1. ‡p  0.05.arasympathetic-sympathetic balance (SD1:SD2 ratio) did Hot differ among the 3 groups (p  0.05) (Fig. 5B, right
anel). Among the subepicardially injected groups, no
ignificant changes in SD1, SD2, and SD1/SD2 were
ound.
On the final study day, all animals showed a significant
ate acceleration upon intravenous epinephrine administra-
ion (1.0 g/kg/min; p  0.05) (Fig. 4C). Furthermore,
uring epinephrine infusion, animals subepicardially in-
ected with HCN2/SkM1 exhibited faster beating rates than
he respective HCN2 group (p  0.05). Similarly, during
baseline and during epinephrine infusion, HCN2/SkM1 LBB-
njected animals showed significantly faster beating rates than
heir respective HCN2 or SkM1 groups (p 0.05). Finally, in
CN2/SkM1 LBB-injected animals, beating rates in base-
ine and epinephrine groups were significantly faster than in
ubepicardially injected animals (p  0.05).
solated tissue studies. Figures 5A and 5B provide repre-
entative examples and summary data from isolated tissue
xperiments conducted on LBB from HCN2-, SkM1- and
e LBB
HCN2 or SkM1
were faster in HCN2/SkM1 than HCN2 and SkM1 groups (). (B) Summary
s were significantly faster in HCN2/SkM1 versus HCN2 or SkM1 (). HCN2/
pective subepicardially injected animals (‡; subepicardially injected animals:
SkM1 n  6, HCN2/SkM1 n  6). (C to E) Left panels show beating rates for
corded in LBB-injected animals. Right panels provide tracings of baseline and
l down in an HCN2-injected animal. (D) Baseline bigeminy and stable maximal
eleration followed by cool down in an animal injected with HCN2/SkM1. Abbre-nto th
d on
rates
nimal
an res
 12,
rate re
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Biological Pacing by HCN2/SkM1 Gene Transfer March 19, 2013:1192–201beating rates did not differ among groups. However, when
isoproterenol was added, HCN2/SkM1-treated preparations
beat faster than the others (p  0.05). With isoproterenol
0.1 M superfusion maintained, we added tetrodotoxin 0.1
M, which selectively blocks SkM1 current (7). Tetrodo-
toxin significantly slowed the HCN2/SkM1-injected prepa-
rations, bringing their beating rates into the same range as
the HCN2-injected preparations (Fig. 5B). This is consis-
tent with a major contribution of SkM1 to the beating rates
in the presence of isoproterenol. During superfusion with
isoproterenol 0.1 M, maximum diastolic potential was
ignificantly more depolarized in HCN2-overexpressing tis-
ue than in tissue that did not overexpress HCN2 (p 0.05)
Fig. 5B).
To test whether threshold potential shifts negatively in
he presence of SkM1, we conducted experiments on dogs
n which viral constructs were injected into myocardium.
igures 6A, 6B, and 6C provide typical tracings and
ummary data. Data acquired from the first 9 action
otentials (APs) per cycle that were stimulated normally
onfirmed the functional presence of SkM1 in the SkM1
nd HCN2/SkM1 groups (Fig. 6C). Specifically, as in
revious reports (6,8), SkM1 overexpression induced an
ncrease in maximal upstroke velocity in the SkM1 and
Figure 3 Detailed Analysis of Rhythms and Their Circadian Mod
(A) Summary data on percentage of pace-mapped beats (percentage matching rhy
mals. Animals that showed 5% of matching beats or persistent bigeminy were exclu
SkM1 n  6, HCN2/SkM1 n  6; LBB-injected animals: HCN2 n  11, SkM1 n 
on morning/night modulation of pace-mapped beating rates. (D) Dependence on elec
bigeminy, and percentage paced are presented as median and interquartile range. Ab
HCN2 and SkM1. ‡p  0.05 versus respective myocardium. §p  0.05 versus respective HCN2/SkM1 groups compared with those in the respec- five noninjected controls and the HCN2-injected group
p  0.05). The 10th AP was generated with a current
ulse that was varied to identify the threshold potential
or AP initiation. Threshold was reached at more nega-
ive voltages in SkM1- and HCN2/SkM1-injected prep-
rations than in noninjected and HCN2-injected controls
p  0.05).
Discussion
Injecting the pacemaker gene HCN2 together with SkM1
nto the LBB has provided a construct that compares
avorably with other biological pacemaker strategies re-
orted to date. With the HCN2/SkM1 biological pace-
aker, rhythms were generated in more than 95% of the
eats, in a canine model with a cardiac rhythm status
omparable to that of patients requiring ventricular
emand pacing. Baseline beating rates were well within a
arget range of 60 to 90 beats/min and demonstrated
risk autonomic responsiveness as evidenced by the
ignificant response to the epinephrine infusion and the
igh level of 24-h HRV. The next step in developing
CN2/SkM1-based biological pacemakers will be to
ove to a delivery system that generates long-term
on
nonmatching beats, bigeminal beats, and electronically paced beats in all ani-
m subsequent analysis (B to D; subepicardially injected animals: HCN2 n  9,
N2/SkM1 n  6). (B) 24-h average rate of matching beats. (C) Summary data
ackup pacing during morning/night. Note that percentage nonmatching, percentage
ions as in Figure 1. *p  0.05 versus respective HCN2. †p  0.05 versus respective
nd HCN2/SkM1. !p  0.05 for morning versus night.ulati
thm),
ded fro
4, HC
tronic b
breviat
CN2 aunction. Such a system may be provided by lentiviral
1197JACC Vol. 61, No. 11, 2013 Boink et al.
March 19, 2013:1192–201 Biological Pacing by HCN2/SkM1 Gene Transfervectors or by HCN2/SkM1-overexpressing human mes-
enchymal stem cells (hMSCs).
SkM1/HCN2 pacemaker function in relation to other
approaches. Outcomes for baseline and maximal rates of
LBB-implanted HCN2/SkM1-based biological pacemak-
ers compared favorably with results reported for AC1 and
various HCN isoforms, mutants, and gene combinations.
Rates with AC1 (4), wild-type HCN2, and genetically
engineered HCN2-E324A, were consistently slower than
with HCN2/SkM1 (2). Although the HCN2/Kir2.1AAA
strategy generated robust pacemaker activity at relatively
rapid baseline beating rates (90 to 95 beats/min), depen-
dence on electronic backup pacing was not eliminated (5).
Further concerns of this strategy include the prolongation of
repolarization induced by Kir2.1AAA (9) and the unknown
degree of autonomic modulation. Although the AC1 strat-
egy shows promise with respect to the high efficiency of
pacemaker function (95% of the beats originated from the
injection site), physiological beating rates (approximately 60
Figure 4 Detailed Analysis of Heart Rate Variability and Respo
(A) Representative Poincaré plots of pace-mapped beats in 24-h Holter recordings
(SkM1-injected animal) also defines SD of instantaneous RR-interval variability (SD
SD1, SD2, and SD1:SD2. Animals that showed 5% of matching beats or persist
n  9, SkM1 n  6, HCN2/SkM1 n  6; LBB-injected animals: HCN2 n  11, Sk
and during epinephrine infusion. Subepicardially injected animals: HCN2 n  10,
HCN2/SkM1 n  6. Abbreviations as in Figure 1. *p  0.05 versus respective HC
SkM1. ‡p  0.05 versus respective subepicardium.beats/min), and high sensitivity to parasympathetic modu-lation, it also manifested relatively slow maximal beating
rates and did not eliminate electronic backup pacing (4).
Moreover, the AC1 strategy elevated cAMP levels and
impacts on calcium handling in cells (10–12), presenting
the potential for unwanted side effects such as triggered
activity and calcium overload. Although we did not see such
side-effects (4), they remain concerns. In contrast, the
HCN2/SkM1 gene combination induced baseline and max-
imal beating rates with ranges that we had targeted as
optimal for a biological pacemaker. We had previously
shown as well that the calcium overload one might fear with
a sodium channel construct was not an issue here (6).
Finally, favorable pacemaker function as manifested by short
escape times and low to absent dependence on electronic
backup pacing was also characteristic of HCN2/SkM1 LBB-
injected animals.
Autonomic modulation of biological pacemaker function.
Autonomic modulation of pacing rates is a potential key
advantage of biological over electronic pacing (8). The
o Epinephrine Infusion
N2, SkM1, and HCN2/SkM1 LBB-injected animals. The middle panel
SD of long-term continuous RR-interval variability (SD2). (B) Summary data of
eminy were excluded from this analysis. Subepicardially injected animals: HCN2
 4, HCN2/SkM1 n  6. (C) Summary data on the beating rates at baseline
n  6, HCN2/SkM1 n  6; LBB-injected animals: HCN2 n  12, SkM1 n  4,
 0.05 for baseline versus epinephrine. †p  0.05 versus respective HCN2 andnse t
of HC
1) and
ent big
M1 n
SkM1
N2. !pextent of autonomic modulation that may be obtained via a
r
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Biological Pacing by HCN2/SkM1 Gene Transfer March 19, 2013:1192–201biological approach likely depends on the gene construct or
the cells used. To facilitate the comparison among the
various biological pacemaker strategies, we analyzed several
measures of autonomic modulation. First, the average base-
line beating rate in the HCN2/SkM1-LBB group was
elatively rapid (approximately 80 beats/min) (Fig. 1), and
he animals maintained robust rate acceleration, reaching
verage maximal rates of approximately 130 beats/min (Fig. 2).
Furthermore, maximal beating rates always remained within
the physiological range, never exceeding 180 beats/min.
This outcome is superior to the slower maximal beating
rates reported here for HCN2 or SkM1 (Fig. 2) and
elsewhere for AC1 (4) in LBB-injected animals, superior to
Figure 5 Tissue Bath Experiments Confirm Critical Role for SkM
Determining Beating Rates of HCN2/SkM1-Injected P
(A) Representative microelectrode traces of LBB preparations from HCN2 (n  5), Sk
under control conditions, after graded application of isoproterenol and after isoprotere
panel) and maximum diastolic potential (right panel). Abbreviations as in Figure 1. *p
for the combined groups with HCN2 (HCN2 and HCN2/SkM1) versus the combined grresults with injection of HCN2/SkM1 into subepicardium(Fig. 2), and superior to the very rapid maximal rates
reported for animals in which the chimera HCN212 and the
combination of HCN2/AC1 were both injected into
LBB (3,4).
Second, we investigated the average beating rates comparing
a period of rest (2:00 to 4:00 AM) with one of physical activity
and feeding (8:00 to 10:00 AM). We found beating rates in
accordance with those expected with a normal response to
circadian modulation (Figs. 3C and 3D). We also found the
ircadian response in the HCN2/SkM1-LBB group to be
uperior to that in animals with LBB gene transfer of HCN2 or
SkM1 and myocardial gene transfer of HCN2/SkM1.
Finally, we investigated sensitivity to parasympathetic
rations
 6), and HCN2/SkM1 (n  6) injected animals and noninjected zones (n  6)
o) 0.1 M plus tetrodotoxin (TTX) 0.1 M. (B) Summary data for beating rates (left
5 versus noninjected. †p  0.05 versus HCN2, SkM1, and noninjected. ‡p  0.05
ithout HCN2 (SkM1 and noninjected).1 in
repa
M1 (n
nol (Is
 0.0
oups wand sympathetic modulation via analysis of HRV and
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March 19, 2013:1192–201 Biological Pacing by HCN2/SkM1 Gene Transferinfusion of epinephrine. The significant reduction in SD2 in
the comparison of HCN2/SkM1-LBB with HCN2-LBB
(Fig. 4B, middle panel) might suggest reduced sensitivity to
sympathetic modulation in the former. However, this is un-
likely given the strong in vitro (Fig. 5) and in vivo (Fig. 4C)
responses to isoproterenol and epinephrine, respectively,
which indicated more profound sensitivity to sympathetic
stimuli in HCN2/SkM1-LBB than HCN2-LBB prepara-
tions. It should be noted that in the HCN2-LBB group,
accelerations (likely induced by sympathetic stimuli) and
Figure 6 SkM1 Overexpression Shifts TP Negatively
Action potential (AP) parameters and threshold potential (TP) were registered from
SkM1-injected and noninjected regions. Preparations were paced at a cycle length
test current pulse (S2) of variable amplitude was substituted for every 10th regula
followed by a 10th AP initiated by a 30-ms suprathreshold current pulse (S2). (B)
current pulses in noninjected, HCN2-, SkM1-, and HCN2/SkM1-injected preparatio
tial amplitude; APD30, APD50, APD90  AP duration to 30%, 50%, and 90% repo
velocity; other abbreviations as in Figure 1. TP was measured for just above thres
tive noninjected.decelerations (likely resulting from reduced biological pace-maker function) were frequently observed at rest, when
beating rates in the HCN2/SkM1 group were relatively
stable. Therefore, it appears likely that sympathetic stimu-
lation during rest in the HCN2/SkM1-LBB group was
below the level of that in the HCN2-LBB group, although
the 24-h average beating rates in the HCN2/SkM1-LBB
group were higher (Fig. 3B). These data indicated that
LBB-injected animals that received HCN2 likely manifested
increased sympathetic activity during rest as a result of their
slower beating rates. The lower average values found for
ntricular subepicardial preparations isolated from HCN2-, SkM1-, or HCN2/
00 ms with 2-ms current pulses at double threshold amplitude (S1). A 30-ms
e. (A) Typical train of 9 APs initiated with 2-ms 2 threshold S1 current pulses
weep recordings of typical tracings of 30-ms subthreshold and suprathreshold
) Summary data on AP parameters and TP measurements. APA  action poten-
on, respectively; MDP  maximum diastolic potential; Vmax  maximum upstroke
rrent amplitude. *p  0.05 versus respective HCN2. †p  0.05 versus respec-left ve
of 1,0
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than reduced sensitivity to sympathetic modulation (13).
Mechanisms underlying pacemaker function based on
HCN2/SkM1 gene transfer. The microelectrode experi-
ments on myocardial bundles obtained from subepicardially
injected animals demonstrated the effect of SkM1 to move
the threshold potential to more negative voltages (Fig. 6).
This observation is significant because shifting the threshold
in this direction would result in AP initiation earlier during
phase 4 depolarization of automatic fibers. Although this
change in AP threshold likely is a major mechanism by
which SkM1 improves pacemaker function, other mecha-
nisms should be considered. For example, SkM1 may help
to reduce current-to-load mismatch that is potentially
present at the interface between transduced and adjacent
nontransduced myocardium. The cardiac sodium channel
Nav1.5 is similarly thought to contribute to pacemaker
mpulse propagation in the sinoatrial node periphery
14,15).
Based on our original hypothesis that SkM1 would
mprove HCN2-based pacemaker function, we expected
nduction of some degree of pacemaker function originating
rom the injection site of SkM1 adenovirus. Yet, we also
ecorded persistent bigeminal rhythms originating from the
njection site (Fig. 3A). The timing of these extra beats at
oupling intervals of 300 to 700 ms and their dependence on
low baseline heart rates (Fig. 3D) is consistent with either
arly afterdepolarizations (16) or re-entry (17). That SkM1-
ssociated bigeminy is not attributable to an SkM1 action
n repolarization was shown in our earlier studies (6,7).
oreover, with the SkM1/HCN2 combination, we saw no
igeminy or other instances of proarrhythmia.
linical applicability. We consider clinical applicability
ith the caveat that the standard for the field is electronic
acing, with its considerable strengths and shortcomings
hat have been described in detail (1). Biological pacing is
eing explored by us and by others as a possible adjunct
o/replacement for electronic pacing. However, a great deal
emains to be done before clinical testing is in order. Given
hat framework, what can be said about the approach
escribed here? Gene transfer of HCN2/SkM1 generated
obust pacemaker function at beating rates close to physio-
ogically desirable levels. The range of function obtained in
he short-term setting of the present study compares favor-
bly to that seen with demand electronic pacing of the
entricle. However, for clinical implementation, the level of
unction that can be generated stably over much longer
erms will be crucial to the success of such an approach. To
his end, one logical next step is the use of the HCN2 and
SkM1 genes in combination with a long-term viral expres-
sion vector such as the lentiviral vector (18). In contrast,
adeno-associated viral vectors cannot support genes the size
of SkM1 without further modifications (19).
In addition, we previously reported the use of MSCs for
the delivery of HCN2 current to myocardium and fabrica-
tion of a cell-based biological pacemaker that functionedstably over 6 weeks (20). In a different study, we also showed
that the SkM1 current can be efficiently delivered to
myocardium via the MSC platform (21). Hence, the MSC
platform offers an alternative means of gene delivery. How-
ever, MSCs show a tendency to migrate from the injection
site, causing a loss of pacemaker function over time. For this
reason, ongoing efforts are focused on the encapsulation of
MSCs, which, if successful, would generate an attractive
delivery vehicle for HCN2 and SkM1 ion channels.
Conclusions
When HCN2/SkM1 was administered to the LBB, pace-
maker function was facilitated by the slow depolarizing
HCN2 current and the hyperpolarized AP threshold gen-
erated by SkM1. This dual gene therapy provided both
highly efficient pacing and a brisk autonomic response to
degrees that appear superior to those of previously devel-
oped gene- or cell-based approaches.
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APPENDIX
For an expanded Methods section, and supplemental
figures and references, please see the online version of this article.
